Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Open-label, Ascending, Sequential Dose Group, Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of CMX157 in HBV-infected Subjects

Next Previous
Search
Trial Profile

A Phase 2, Randomized, Open-label, Ascending, Sequential Dose Group, Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of CMX157 in HBV-infected Subjects

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenofovir exalidex (Primary) ; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors ContraVir Pharmaceuticals; Hepion Pharmaceuticals

Most Recent Events

  • 24 Oct 2017 Results of phase IIa portion of this study presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
  • 12 Sep 2017 Status changed from recruiting to completed.
  • 08 Aug 2017 According to a ContraVir Pharmaceuticals media release, data from the study will be presented at the American Association for the Study of Liver Diseases (AASLD).

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top